Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Steven Trifilio*, Zheng Zhou, Jessica Altman, Olga Frankfurt, Mihaela Pantiru, Jayesh Mehta

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

Original languageEnglish (US)
Pages (from-to)872-876
Number of pages5
JournalLeukemia Research
Volume37
Issue number8
DOIs
StatePublished - Aug 2013

Keywords

  • Acute myeloid leukemia
  • Complete remission
  • Cyclophosphamide
  • Etoposide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this